Cite
HARVARD Citation
Siegmund, B. et al. (n.d.). S766 The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis. American journal of gastroenterology. pp. e543-e544. [Online].